Business Context and Reporting Period
Zenas BioPharma, Inc. (ZBIO) is a clinical-stage biopharmaceutical company focused on developing immunology and inflammation (I&I) therapies. The company completed its Initial Public Offering (IPO) in September 2024. This Form 10-Q covers the quarterly period ended March 31, 2025. The company is currently developing its lead product candidate, obexelimab, for indications including IgG4-related disease (IgG4-RD), relapsing multiple sclerosis (RMS), and systemic lupus erythematosus (SLE).
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Total Revenue | $10.0 million | $0 |
| Net Loss | $(33.6) million | $(27.8) million |
| Net Loss Per Share (Basic & Diluted) | $(0.80) | $(17.89) |
| Operating Expenses | $47.3 million | $27.6 million |
| Cash, Cash Equivalents, and Investments | $314.2 million | $350.8 million |
| Accumulated Deficit | $(421.0) million | $(258.2) million |
Cash Flow: Net cash used in operating activities was $37.1 million. Net cash used in investing activities was $86.3 million, primarily due to the purchase of investments ($99.1 million) partially offset by proceeds from sales and maturities ($12.9 million).
Material Changes vs. Prior Period
- Revenue Recognition: The company recognized $10.0 million in license and collaboration revenue in Q1 2025, compared to zero in Q1 2024. This was driven by a one-time non-refundable upfront payment from a new license agreement with Zai Lab (Hong Kong) Limited entered into in January 2025.
- Operating Expenses: Total operating expenses increased by $19.8 million (72%) year-over-year.
- R&D Expenses: Increased by $12.3 million to $34.9 million, primarily due to a $11.2 million increase in costs for the lead candidate obexelimab (clinical trial and manufacturing costs).
- G&A Expenses: Increased by $7.5 million to $12.4 million, driven by higher personnel costs (including stock-based compensation) and professional fees associated with operating as a public company.
- Liquidity: Cash and investments decreased by approximately $36.6 million from the prior year-end, reflecting operating burn and net investment purchases.
Guidance, Outlook, and Risks
Outlook and Liquidity: Management expects to continue incurring significant losses for the foreseeable future. As of March 31, 2025, the company had $314.2 million in cash, cash equivalents, and investments. Management believes these resources are sufficient to fund operations and capital expenditure requirements into the fourth quarter of 2026.
Key Risks and Contingencies:
- Capital Requirements: The company will require substantial additional financing to achieve its goals. Failure to obtain capital could force delays or termination of product development.
- Manufacturing Concentration: The company relies on a single third-party manufacturer, WuXi Biologics (located in China), for drug substance and drug product. Risks include geopolitical tensions, potential tariffs, and the proposed BIOSECURE Act, which could restrict U.S. federal contracts with certain Chinese biotechnology companies.
- Regulatory and Clinical Uncertainty: Clinical development is lengthy and expensive. The company faces risks regarding patient enrollment, trial outcomes, and regulatory approval for obexelimab and other candidates.
- Legal Proceedings: A putative securities class action lawsuit was filed in April 2025 against the company and certain directors/officers regarding the IPO. The company does not anticipate providing updates absent a legal obligation.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $314.2 million cash balance against projected burn rates to confirm the "fourth quarter of 2026" liquidity estimate.
- Manufacturing Strategy: Assess the progress of establishing alternative U.S.-based contract manufacturing organizations (CMOs) to mitigate reliance on WuXi Biologics and potential regulatory risks under the BIOSECURE Act.
- Revenue Sustainability: Confirm that the $10.0 million revenue recognized in Q1 2025 was a one-time upfront payment and review the probability of achieving future milestone payments from the Zai Lab, Tenacia, and BMS agreements.
- Legal Exposure: Monitor the status of the April 2025 securities class action litigation and potential impacts on insurance costs or settlement liabilities.
- Obexelimab Progress: Track enrollment and data readouts for the Phase 3 trial in IgG4-RD and Phase 2 trials in RMS and SLE, as these are critical value drivers.